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he use of psychostimulants in the therapy of
treatment-resistant depression in addition to conven-
tional antidepressants is not very common and has
been criticized by some authors. In Germany,Austria,
and Switzerland, depression is not a listed indication
for the use of psychostimulants. In contrast, at the
Zurich Psychiatric University Hospital, dextroam-
phetamine and ritalin have been used since the thir-
ties to treat severe cases of treatment-resistant
depression, especially in the presence of prominent
fatigue and apathy, and psychostimulants are now well
established as an adjuvant therapy. This article
reviews the literature on the use of psychostimulants
in treatment-resistant depression and discusses the
findings relative to therapeutic efficacy, side effects,
and frequency of dependency from a retrospective
study carried out in 65 patients of our hospital treated
with psychostimulants.
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Gabriele STOTZ
The use of psychostimulants as an adjuvant therapy in treatment-resistant depression is not very common nowa-
days and has been the subject of much criticism. This article gives a brief review of the literature and reports on
the findings from a retrospective study carried out in 65 depressed patients treated with psychostimulants
(amphetamine and methylphenidate) in addition to conventional antidepressants. Thirty-eight out of 65
patients showed significant improvement, in particular with respect to energy, mood, and psychomotor activ-
ity. The best response to psychostimulants was seen in inhibited types of depression and in combination with
a tricyclic antidepressant. None of the patients developed drug dependency. The incidence of side effects was
low, and agitation and restlessness improved with an additional short-term treatment with benzodiazepines.
It is concluded that the rapid onset of action (2-3 hours) after administration may help cover the therapeutic
latency period of conventional antidepressants and probably potentiates their effect. In view of their potential
benefits in treatment-resistant depressive states, psychostimulants should be tried more often. 
Keywords: psychostimulant; adjuvant therapy; treatment-resistant depression;
combination with tricyclics; dependency; rapid onset; potentiation of antidepres-
sant effect
TReview of the literature
Historical background
Amphetamine was first synthesized in 1887, with the
first significant clinical  investigations being performed
in 1927.
1 The drug was used as a bronchodilator in
asthma,as an appetite suppressant,for narcolepsy,and,
paradoxically, was discovered in the 1930s to alleviate
the hyperactive syndrome in children.
Since the 1930s, amphetamine and its derivatives
methylphenidate and pemoline have been used in
affective disorders,obsessive-compulsive disorders,and
in schizophrenia (for a review see ref 2) (Figure 1).
However,in the 1950s,psychostimulants were replaced
by the newly developed antidepressants.Their use was
reduced still further in the 1960s, as these drugs were
being increasingly abused.
3,4 In recent years, the use of
psychostimulants in psychiatry has been limited to the
therapy of attention deficit disorder (for a review see
ref 5), refractory obesity, and narcolepsy. Most psychi-
atrists today are not familiar with the potential useful-
ness of psychostimulants in the therapy of treatment-
resistant depression.
Pharmacology
Amphetamine increases the release of biogenic
amines, exerts direct agonistic effects on presynaptic
central receptors for 5-hydroxytryptamine (5-HT),
and has a mild inhibiting effect on monoamine oxi-
dase.
6,7 Thus, from a pharmacological viewpoint, psy-
chostimulants complete and amplify the effect of
conventional antidepressants
8-14 and are assumed to
increase the blood levels of certain antidepressants
through their action on hepatic hydroxylation.
13
Psychostimulants are rapidly absorbed following oral
administration. At standard therapeutic doses (10 to
15 mg for amphetamine and 10 to 60 mg for
methylphenidate), peak effects are found 2 to 3 hours
after ingestion. Psychostimulants are metabolized by
rapid oxidative deamination to benzoic acid and hip-
puric acid.
Clinical effects
The greatest improvement reported following treat-
ment with psychostimulants is in motor activity, mood,
and psychomotor activity.
15-17An improvement in mem-
ory and concentration may be observed, in some cases
accompanied by euphoria.
18
The onset of action of psychostimulants is usually
observed clinically within 30 minutes to 1 or 2 hours
following administration,
19-23 and their effects last about
4 hours.
24
Patient response is heterogeneous, with variations in
sensitivity due to individual differences in biological
and genetic parameters.
25 The use of psychostimulants
must be carefully monitored.
10 Patient response also
depends on which type of psychostimulant is admin-
istered, and if no therapeutic effect is observed with
one drug, another one may prove effective. Further-
more, patient response to a given psychostimulant
may vary from year to year.
16 One feature of particular
interest is that the response to amphetamines may be
predictive of the therapeutic effect of tricyclic drugs in
depressed patients, since both types of drugs have sim-
ilar mechanisms of action (rapid for the amphetamines,
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Figure 1. Structure of amphetamine and methylphenidate.167
slower for the tricyclics) involving an increase in free
norepinephrine levels.
19 In contrast, the response to
methylphenidate does not appear to be predictive of
antidepressant efficacy.
26
Side effects
At low doses (2-10 mg per day), amphetamine can
induce sleep and libido disturbances as well as nausea,
tremor, agitation, and restlessness.
At higher doses (30-60 mg per day), amphetamine
may induce anxiety, psychoses, exhaustion symptoms
with fatigue and drowsiness after the stimulation
phase, prolonged depression, and prolonged halluci-
nosis
27 whereby the individual continues to hallucinate
after the drug has been metabolized.
28
Extein
29 described choreoathetosis after administra-
tion of psychostimulants in one patient, probably by
potentiation of central dopaminergic activity. Because
of the release of norepinephrine and dopamine
induced by the psychostimulants, the appearance of
stereotypic movements and tics is theoretically possi-
ble however, these have only been reported in ani-
mal experiments in the literature. Other possible yet
rare side effects are hyperthermia and pulmonary
hypertension
7,30 and, even more rarely, cardiovascular
shock and stroke.
31 Natenshon
24 and Ferguson and
Funderburk
32 did not observe any effect on the car-
diovascular system in their patients. They found nei-
ther advanced age nor cardiac disease to contraindi-
cate the use of psychostimulants.
Wilbur
33 noted declining efficacy of stimulants over
time; most other authors, however, reported no evi-
dence of waning of effect in depressed patients treated
with 5 to 60 mg methylphenidate for up to 1 year.
24Tol-
erance was seen only in relation to effects like hyper-
thermia,hypertonia,and anorexia,but not psychomotor
stimulation.
31,34,35
It should be stressed that the aforementioned side
effects are observed not only in depressed patients,
but also in patients treated with psychostimulants for
other indications.
Development of dependency or tendency to abuse?
The possible development of dependency and a with-
drawal syndrome after withdrawing amphetamines has
been a controversial issue. Addiction was reported by
Kramer et al
3 and Edison,
36 and a withdrawal syndrome
characterized by apathy, decreased activity, and sleep
disturbances with an increase in rapid eye movement
(REM) sleep by Oswald and Thacore
37 and Watson et
al.
38 Most studies, however, report little or no depend-
ence in depressed patients treated with amphetamines
(see overview in refs 2 and 23).Psychostimulants may be
withdrawn after several weeks of treatment without any
danger of recurrence of depression.
21 No tolerance or
addiction has been reported to develop in geriatric
patients.However,recurrence of mild depression,tired-
ness,and anxiety have been reported on stopping treat-
ment with psychostimulants.
39 Development of tolerance
or abuse after patients are discharged from hospital is
practically never reported.
22,24,40
Dosage
The dosage of the psychostimulants must imperatively
be individually adjusted. The daily doses usually rec-
ommended in treatment-resistant depressed patients
range between 2.5 mg
41 and 15 mg
20 for amphetamine
and between 10 and 60 mg for methylphenidate.
42
Indications in depressive disorders
Some depressive disorders remain refractory to treat-
ment despite intensive antidepressant therapy with ade-
quate dosages and even combinations of antidepres-
sants.
43,44 These cases may benefit from adjuvant
treatment with psychostimulants. The mood-elevating
effects of the tricyclics, selective serotonin reuptake
inhibitors (SSRIs), and monoamine oxidase inhibitors
(MAOIs) usually only manifest after 10 to 12 days.Side
effects and drug interactions are quite common with
these drugs. Although psychostimulants themselves are
not as effective as conventional antidepressants,
45,46 they
have the dual advantage of a more rapid onset of action
and of inducing a lower rate of adverse events.
Because their acute effects develop within less than a
few hours,
20 they may be used in combination with tra-
ditional antidepressants in order to cover the latter's
therapeutic latency period and potentiate their effect.
13,35 
In a review of the literature,Chiarello and Cole
2 showed
that the majority of studies—even though some were
methodologically unsatisfactory—reported beneficial
effects following administration of psychostimulants in
treatment-resistant depression.
15,22,31,34,35,47-52 Nevertheless,
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placebo could be demonstrated in any of the placebo-
controlled studies.Some authors have reported lack of
effect or even deterioration following the addition of
psychostimulants.
53-56
Beneficial effects have been described in particular in
depression with marked apathy in elderly patients.
32,52,57-60
Administration of psychostimulants appears to enhance
the efficacy of concomitant (analytically orientated)
psychotherapy in elderly patients by facilitating com-
munication and cooperation through their mood-ele-
vating effects.
31
Psychostimulants are suggested to be of significant
value in the management of depression in the elderly as
well as in depressed patients with concomitant somatic
disorders,
14,21,22,60 and good results have been reported in
the treatment of secondary depressions triggered by
preexisting somatic diseases.
4,21,40,61
Psychostimulants have been shown to be effective in
patients with mild depressive symptoms in an outpa-
tient setting.
15,55,62
According to Rudolf,
49,63 the addition of psychostimu-
lants in patients with treatment-resistant depression
receiving conventional antidepressants is superior to
electroconvulsive therapy (ECT).Kerenyi et al
15 reported
methylphenidate to be useful in combination with ECT.
Inhibited patients and depressed patients with bipolar
disorder seemed to benefit most from adjuvant treat-
ment with psychostimulants.
15 The response to psy-
chostimulants in patients suffering from neurotic and
agitated depression seems to be less satisfactory. Nev-
ertheless, there is no contraindication to psychostimu-
lants in agitated depression.
64
The combination of psychostimulants with tricyclics and
MAOIs has been a very controversial issue. Some
authors have criticized the combination of psychostim-
ulants and MAOIs on the basis of the possible devel-
opment of an adrenergic crisis or the serotonin syn-
drome. The Physicians’ Desk Reference even warned
against such drug combinations in 1983 because of the
possibility of hypertensive crises,which,however,were
found to be very rare.
35
In contrast with the above reports, several series of
open clinical trials showed the combination of psycho-
stimulants and MAOIs to be safe (see review in refs 35,
65-67). More recently, authors such as Chiarello and
Cole
2 and Little
68 have stressed the frequent effective-
ness of the combination of psychostimulants and
MAOIs in treatment-resistant depression.
Findings from a retrospective study 
in 65 depressed patients
Subjects and methods
In a retrospective study, we evaluated all the medical
records since the 1950s of patients at the Zurich Psychi-
atric Hospital who had received psychostimulants
because of treatment-resistant depression (defined by
Woggon
44 as lack of improvement despite treatment with
at least two different antidepressants in adequate dosage
for more than 4 weeks). A total of 65 patient records
were analyzed (20 males and 45 females).The average
age of male patients was 50 years, and that of female
patients was 55 years. At the time of treatment, the
patients were either hospitalized (inpatients) or under-
going ambulatory treatment as outpatients.
The patients who had received psychostimulants were
identified from the hospital pharmacy records,which list
the names of all patients having received drugs classified
as narcotics. In earlier years, classifications of mental
diseases such as the International Classification of Dis-
eases (ICD) or Diagnostic and Statistical Manual of
Mental Disorders (DSM) were not yet available, and
diagnoses were descriptive only.Therefore, the classifi-
cation in this retrospective study had to be done on a
syndrome basis. The types of depression for which the
patients had been treated with psychostimulants because
of their refractory character were (in order of descend-
ing frequency): inhibited depression (50), anxious
depression (39), agitated depression (21), depression
with somatization (21),neurotic depression (20),bipolar
disorder (16), and depressive states in schizoaffective
disorders (4) with overlapping in symptomatology.
Because of the small number of subjects (65 patients,
17 treated with amphetamines,35 with methylphenidate,
and 13 treated with both amphetamines and methyl-
phenidate), and because a separate statistical analysis
of patients treated with amphetamines and those treated
with methylphenidate failed to show any significant dif-
ference between both groups, it was decided to subsume
treatment with amphetamines and with methylphenidate
as “treatment with psychostimulants” for the purpose of
the study.
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treatment (conventional antidepressants and psycho-
stimulants) was 128 months (10 years, with a median of
84 months (7 years). Seventeen patients were treated
with amphetamine, 35 with methylphenidate, and 13
with both amphetamine and methylphenidate, either
concomitantly or one after the other.
Regarding conventional antidepressant therapy, prior
to receiving psychostimulant treatment, 3 patients had
been administered one,6 patients two,10 patients three,
6 patients four, and 39 patients five or more antide-
pressants at various dosages. In 35 of the 65 patients,
additional treatment modalities (such as sleep depriva-
tion therapy, light therapy, and ECT) had been used.
Psychostimulants were given in combination with tri-
cyclic antidepressants in 48 cases,with SSRIs in 35 cases,
with MAOIs in 8 cases, with lithium in 35 cases, and
with carbamazepine in 22 cases.(Some patients received
two or more antidepressants and mood stabilizers, in
combination with the psychostimulants.)
Dosage was titrated individually and modified during
therapy.Patients treated with amphetamines received an
average dosage of between 5 and 10 mg per day,the min-
imum being between 5 and 10 mg,and the maximum 20
mg per day.The average dosage of methylphenidate was
10 to 20 mg per day,with a minimum of 10 mg,and max-
imum of 40 mg per day.In 25 (out of 64) cases the dosage
was increased, in 14 cases it remained unchanged, in 14
cases it was reduced,and in 11 cases it was discontinued.
The average duration of psychostimulant therapy was
46 months (approximately 4 years) in the amphetamine
group and 57 months (approximately 5 years) in the
methylphenidate group. In most cases the treatment
was continuous.
Patient characteristics are summarized in Table I .
Results
Thirty-eight patients improved on treatment with psy-
chostimulants,whereas 26 remained unchanged or dete-
riorated.
It must be pointed out that no rating scales or self-rating
scores had been used in the patients, since it was not
common in the fifties or earlier to evaluate a patient's
condition with scales. Patient records therefore only
allowed the course of the disease to be qualified as “bet-
ter,” “unchanged,” or “worse.” In this way it could be
shown that there was no significant differences between
the different age-groups in terms of outcome (chi-square
test and analysis of variance for nonparametric samples).
Amphetamine Methylphenidate Both
Number of patients 17 35 13
Male (n) 3 15 2
Female (n) 14 20 11
Age in years (median) 51 49 51
Age of onset in years (median) 37 37 37
Benzodiazepines (n) 21 36
Psychostimulant therapy in months (median)   46 5 7
Inhibited/anxious depression (n) 11 25 7
Agitated depression (n) 6 10 6
Table I. Retrospective study; patient characteristics (n=65). 
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sion, we looked at the distribution of patients in terms
of response to psychostimulant treatment with respect
to syndrome (agitated depression and inhibited/anx-
ious depression), and with respect to diagnosis (unipo-
lar disorder and bipolar disorder) (Table II). The best
response to psychostimulant treatment was seen in the
group of inhibited and anxious types of depression (27
out of 42 patients improved). In the group of patients
with agitated depression, 11 out of 22 patients were
improved. Finally, 8 out of 16 patients with bipolar
depression were improved.
Looking now at improvement in the course of depres-
sion according to the type of treatment the psychos-
timulant drug was added on to,improvement was noted
in 6 out of 8 patients who were treated with a psycho-
stimulant and an MAOI,in 30 out of 48 patients treated
with a psychostimulant and a tricyclic, in 21 out of 35
patients treated with a psychostimulant and an SSRI,in
21 out of 35 patients treated with a psychostimulant
and lithium, and in 12 out of 22 patients treated with a
psychostimulant and carbamazepine.
Additional treatment with benzodiazepines was
required in 21 out of 30 patients treated with ampheta-
mines and in 36 out of 48 patients treated with
methylphenidate (13 patients received both drugs).
Overall,the frequency of adverse events and side effects
was higher in patients treated with methylphenidate
than in patients treated with amphetamines. However,
methylphenidate was prescribed in most cases to out-
patients and at a relatively higher dosage. Side effects
were reported in 51 out of 65 patients treated with psy-
chostimulants, including nausea and headache in 32
patients, restlessness in 29 patients, agitation in 25
patients, sleep disturbances in 18 patients, and circula-
tory disorders in 6 patients. In all cases blood pressure
remained unchanged before, during, and after treat-
ment with psychostimulants.
It has to be taken into consideration, however, that it
was not always possible to differentiate between the
side effects attributable to the psychostimulants and
those attributable to the antidepressants.
None of the depressed patients developed drug depend-
ency or addictive behavior. To test for this possibility,
psychostimulant treatment was withdrawn, in most
patients, at least once during the course of treatment
for a period of 2 days,during which the patients experi-
enced apathy and tiredness,but without developing any
craving for psychostimulant or signs of withdrawal.
In the 38 patients who experienced a beneficial effect
from treatment with psychostimulants, 35 patients
reported an improvement in energy, 26 in mood, 26 in
motor activity, 15 in symptoms of psychomotor retar-
dation,11 in vigilance,and 7 in social interactions.Neg-
ative symptoms did not improve in the 4 patients with
schizoaffective disorders.
Discussion
Our study highlights the benefit of the administration of
psychostimulants in addition to conventional antide-
pressants in patients with treatment-resistant depres-
sion. These findings are concordant with those of the
majority of open studies (see the review of the litera-
ture in the first part of this paper).There were no severe
side effects and only a low incidence of mild and mod-
erate side effects in the patient population we studied,
in agreement with the findings described in the litera-
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Better Unchanged/Worse Total
Syndrome
Agitated 11 11 22
Inhibited/anxious 27 15 42
Diagnosis
Unipolar 30 18 48
Bipolar 8 8 16
Table II. Effects during treatment with psychostimulants (n=65).ture. Unlike Kramer et al
3 and Edison,
36 we found no
evidence of drug dependency in our patients.
Some of our patients were suffering from concomitant
somatic illnesses. These patients probably benefited
from the treatment with psychostimulants, as reported
by Woods et al
22 in their sample of patients with depres-
sive disorders secondary to somatic illnesses.
There were no severe cardiovascular disturbances in
our patients.
In several studies in the literature, psychostimulants
were used preferentially in elderly persons.In our study,
both  elderly and younger patients were treated with
psychostimulants, with the same positive effect.
No psychoses (as opposed to Lucas and Weiss
27) were
observed in any of our patients treated with psychos-
timulants.
Some of the patients of our study (6 out of 8) responded
positively to combined treatment with (reversible)
MAO-A inhibitors (like moclobemide) and psychos-
timulants, even though this particular combination is
regarded as controversial.The positive effect of a com-
bination of psychostimulants with tricyclic antidepres-
sants (as recommended by Spencer
69 and Woggon
70)was
confirmed in our study (30 of 48 patients treated with
tricyclics and psychostimulants showed improvement).
In agreement with Wharton et al
13 and Feighner et al,
35
we believe that combining a psychostimulant and a tri-
cyclic antidepressant potentiates the action of the lat-
ter through an increase in the serum levels of its active
metabolites.According to another hypothesis,the bene-
ficial effect could be secondary to an increase in
monoamine concentrations in the synaptic cleft.
In our experience, use of psychostimulants in agitated
depression may be of benefit, although more rarely so
than in inhibited depression, thus confirming the find-
ings of Kerenyi.
15We also agree with Ward and Lampe
64
that there is no contraindication to the use of psychos-
timulants in agitated depressed states. Like Wilbur,
33
but in disagreement with Wheatley,
50 we have also used
psychostimulants in neurotic depression, again with
lower rates of success.Finally,we have found that treat-
ment with psychostimulants in an outpatient clinical
setting was possible without any problems in some of
our patients, a finding in keeping with previous studies
of Kerenyi,
15 Rickels et al,
62 and Mattes.
55
Conclusions
Based on a retrospective study carried out in 65 patients
suffering from treatment-resistant depression, we con-
firm that treatment with psychostimulants in addition to
conventional antidepressants has a beneficial effect on
the outcome of depression. Not all the patients in our
study showed a significant improvement,but the major-
ity (38 out of 65 patients) did. None of the patients
developed drug dependency or withdrawal symptoms.
The overall incidence and severity of side effects was
low.In patients in whom agitation or restlessness devel-
oped, a dosage-reduction and/or additional short-term
treatment with benzodiazepines proved consistently
helpful.Apathy improved in a satisfactory way in most
of the patients and in most cases within the first hours
following administration. The rapid onset of action of
the psychostimulants has the advantage of covering the
therapeutic latency period of conventional antidepres-
sants and potentiating their effect. Psychostimulants
should be preferably combined with tricyclic antide-
pressants. In some cases, an increase in dosage of con-
ventional antidepressants can be avoided by taking
advantage of the potentiating and additive effect of the
psychostimulants.
Although adjuvant therapy with psychostimulants in
patients suffering from treatment-resistant depression
has not yet become established in clinical practice, we
believe that it should be tried more often in view of its
potential benefits.❏
For relevant information concerning the review of literature I thank 
Dr Martin Preisig, from Lausanne
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Fármacos psicoestimulantes en el
tratamiento de la depresión resistente
Análisis de la literatura y resultados 
de un estudio retrospectivo en 
65 pacientes con depresión 
El uso de psicoestimulantes como fármacos potenci-
adores en el tratamiento de las depresiones resistentes
no es muy frecuente en la actualidad y sigue siendo
motivo de críticas.Este artículo revisa parte de la liera-
tura y refiere los resultados de un estudio retrospectivo
realizado en 65 pacientes con depresión que reci-
bieron psicoestimulantes (anfetamina y metilfenidato)
además de antidepresivos convencionales. Treinta y
ocho pacientes mostraron una mejoría significativa de
la energía, el ánimo y la actividad psicomotora. La
mejor respuesta a los psicoestimulantes se observó en
los pacientes con depresión inhibida que recibieron
tricíclicos. Ninguno de los pacientes desarrolló una
farmacodependencia. La incidencia de efectos adver-
sos fue baja; la agitación e inquietud se redujeron con
benzodiazepinas utilizadas por poco tiempo. Se con-
cluyó que el rápido inicio de la acción de los psicoes-
timulantes (2 a 3 horas) luego de su administración,
puede ayudar a cubrir el período de latencia terapéu-
tica de los antidepresivos convencionales y probable-
mente potencie el efecto de estos últimos. Los psicoes-
timulantes debieran utilizarse con más frecuencia en el
tratamiento de la depresión resistente considerando
sus potenciales ventajas.
Les psychostimulants dans le traitement
des dépressions résistantes
Revue de la littérature et résultats obtenus à
partir d’une étude rétrospective chez 65 patients
déprimés
L’utilisation des psychostimulants comme traitement
adjuvant des dépressions résistantes n’est pas très
fréquente de nos jours et a été largement critiquée.Cet
article donne un aperçu rapide de la littérature et rap-
porte les résultats d’une étude rétrospective menée
chez 65 patients dépressifs cotraités par psychostimu-
lants (amphétamine et méthylphénidate) et antidé-
presseurs classiques. Trente-huit patients sur 65 ont
montré une amélioration significative, en particulier,
en ce qui concerne l’énergie, l’humeur et l’activité
psychomotrice. La meilleure réponse aux psycho-
stimulants a été notée pour les dépressions ralenties et
en association avec un antidépresseur tricyclique.
Aucun des patients n’a développé de phénomène de
dépendance.La fréquence des effets secondaires était
faible, et l’agitation et la nervosité ont été améliorées
par une prescription de courte durée de benzodi-
azépines. En conclusion, la survenue rapide (2 à 3
heures) de l’effet après la prise pourrait aider à cou-
vrir la période de latence thérapeutique des antidé-
presseurs classiques et, probablement, potentialiser
leurs effets. Vu leurs bénéfices potentiels dans le
traitement des dépressions résistantes, les pychotimu-
lants devraient être plus fréquemment utilisés.173
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